SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (16868)5/19/2005 3:11:53 PM
From: former_pgs  Read Replies (2) | Respond to of 52153
 
I think at ASCO a couple of years ago, there was a retrospective analysis looking at response rates versus survival in cancer trials. Their bottom line was that complete responses were a much better surrogate of survival than the overall response rate or partial responders. This is somewhat intuitive since the threshold for a partial response is arbitrary.

Unfortunately i do not have a link.

For examples of trials that have shown correlation of TTP and survival, Velcade's APEX trial and OSIP's BR2.1 trial did so. To also show the flakiness of response rate, the Velcade trial showed increased RR and increased survival, whereas the Tarceva trial showed increased survival and no increase in RR.



To: Biomaven who wrote (16868)5/19/2005 5:24:24 PM
From: DewDiligence_on_SI  Respond to of 52153
 
I think the short answer is that TTP generally does correlate with survival, and likely RR does to. But it may well vary by cancer type.

In general the correlation between RR and survival is stronger for chemo drugs than it is for “targeted” therapies.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News